Skip to main content
Clinical Trials/NCT04178993
NCT04178993
Completed
Phase 1

A Novel Drug Combination as a Pharmacotherapeutic for Methamphetamine-Use Disorder

Craig Rush2 sites in 1 country8 target enrollmentSeptember 1, 2019

Overview

Phase
Phase 1
Intervention
Methamphetamine
Conditions
Methamphetamine Use Disorder
Sponsor
Craig Rush
Enrollment
8
Locations
2
Primary Endpoint
Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance.
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study will evaluate the behavioral effects of methamphetamine during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.

Registry
clinicaltrials.gov
Start Date
September 1, 2019
End Date
May 5, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Sponsor
Craig Rush
Responsible Party
Sponsor Investigator
Principal Investigator

Craig Rush

Professor

University of Kentucky

Eligibility Criteria

Inclusion Criteria

  • recent use of inhaled (i.e., snorted), smoked or injected methamphetamine

Exclusion Criteria

  • Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant.
  • Current or past histories of substance use that are deemed by the study physicians to interfere with study completion.
  • History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation.
  • Females not currently using effective birth control.
  • Contraindications to methamphetamine, methylphenidate, or duloxetine.

Arms & Interventions

Placebo Comparator: Placebo

Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.

Intervention: Methamphetamine

Placebo Comparator: Placebo

Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.

Intervention: Methylphenidate

Placebo Comparator: Placebo

Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.

Intervention: Placebo oral capsule

Active Comparator: Duloxetine

Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.

Intervention: Methamphetamine

Active Comparator: Duloxetine

Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.

Intervention: Methylphenidate

Active Comparator: Duloxetine

Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.

Intervention: Placebo oral capsule

Active Comparator: Duloxetine

Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.

Intervention: Duloxetine

Outcomes

Primary Outcomes

Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance.

Time Frame: Following at least 4 days of maintenance on placebo during inpatient admission, up to 1 week

Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).

Reinforcing Effects of Methamphetamine Following Methylphenidate (60 mg) Maintenance.

Time Frame: Following at least 4 days of maintenance on drug during inpatient admission, up to 1 week

Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have the ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).

Reinforcing Effects of Methamphetamine Following Methylphenidate (20 mg) Maintenance.

Time Frame: Following at least 4 days of maintenance on drug during inpatient admission, up to 1 week

Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have the ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).

Reinforcing Effects of Methamphetamine Following Methylphenidate (40 mg) Maintenance.

Time Frame: Following at least 4 days of maintenance on drug during inpatient admission, up to 1 week

Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have the ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).

Secondary Outcomes

  • Heart Rate After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Heart Rate After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Heart Rate After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Heart Rate After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Temperature After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Temperature After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Temperature After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (0 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (60 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Temperature After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (20 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (0 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (0 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (20 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (40 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (60 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (20 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (40 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (40 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)
  • Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (60 mg) Maintenance.(Daily over approximately 1 week of inpatient stay.)

Study Sites (2)

Loading locations...

Similar Trials